ArticleRNA (New York, N.Y.)2005
Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.
Article in RNA (New York, N.Y.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 96 citations in OpenAlex.
- From Selection to Use: Aptamers as Targeting Reagents in Hematology.Biomedicines · 2026Review
- KSHV and cancer: understanding the oncogenic machinery for next-generation diagnostic tools and therapies.Archives of microbiology · 2026Review
- Insulin Quantification Through Electrochemical and Optical Aptasensors: A Review.Annals of biomedical engineering · 2025Review
- Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers.Molecular therapy. Nucleic acids · 2025Review
- Oral delivery of RNAi for cancer therapy.Cancer metastasis reviews · 2023Review
- Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents.Molecular therapy. Nucleic acids · 2023Article
- Aptamer-Based Gold Nanoparticles-PDMS Composite Stamps as a Platform for Micro-Contact Printing.Biosensors · 2022Article
- Liquid Crystal Biosensors: Principles, Structure and Applications.Biosensors · 2022Review
- Aptamers for Viral Detection and Inhibition.ACS infectious diseases · 2022Review
- Novel Biorecognition Elements against Pathogens in the Design of State-of-the-Art Diagnostics.Biosensors · 2021Review
- Aptamer Laden Liquid Crystals Biosensing Platform for the Detection of HIV-1 Glycoprotein-120.Molecules (Basel, Switzerland) · 2021Article
- Aptamers for Anti-Viral Therapeutics and Diagnostics.International journal of molecular sciences · 2021Review
- Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases.Frontiers in bioengineering and biotechnology · 2021Review
- Liquid Crystal Based Binding Assay for Detecting HIV-1 Surface Glycoprotein.Frontiers in chemistry · 2021Article
- Pharmaceutical Approaches to HIV Treatment and Prevention.Advanced therapeutics · 2018Article
- Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Oligonucleotide aptamers: promising and powerful diagnostic and therapeutic tools for infectious diseases.The Journal of infection · 2018Review
- Aptamers in HIV research diagnosis and therapy.RNA biology · 2018Review
- Review
- Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.Pharmaceuticals (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently described the isolation of 2'-fluoropyrimidine-substituted RNA aptamers that bind specifically to the surface glycoprotein (gp 120) of the R5 strain, HIV-1(Ba-L), as presented in a previous study. These aptamers potently neutralize HIV-1 infectivity in human peripheral blood mononuclear cells of both tissue culture lab-adapted strains and diverse R5 clinical isolates from multiple clades. Here, we report a detailed structural characterization of one such neutralizing aptamer, B40, using enzymatic and chemical probing methods. We identify the minimal region of the aptamer essential for binding gp120 and accordingly design a 77-nucleotide truncated aptamer, B40t77. We then quantitatively analyze the binding affinity and neutralization potency of the parental and truncated (minimal) aptamer, and show them to be comparable. Furthermore, using results from secondary structure analysis, RNA mutagenesis and BIAcore surface plasmon resonance (SPR) binding assays, we hypothesize that a folded RNA structure is required to present specific nucleotide sequences to allow gp120-recognition and binding. The information gained from this study may provide leads for development of novel anti-HIV-1 therapies and can be used to extend our understanding of the molecular interactions between the virus and its host cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.